Riskpilot← Back to searchSign inGet full accessSwan Neck Bio ApS
APSActiveCVR 44258285Kirstinehøj 1Manufacture of other food products n.e.c. · NACE 1089Est. 20239 employees
Revenue 2025
DKK -225K
-43% vs 2024
EBITDA margin
2324.1%
-46% vs 2024
Equity ratio
81.4%
Financial strength
Net profit 2025
DKK -5,6M
-56% vs 2024
| Revenue | DKK -225K | -43% |
| EBITDA | DKK -5,2M | -46% |
| Net profit | DKK -5,6M | -56% |
| Total assets | DKK 20,1M | +1218% |
| Equity | DKK 16,4M | +3538% |
| Employees | 9 | — |
Legal name
Swan Neck Bio ApS
CVR number
44258285
Legal form
Anpartsselskab
NACE code
1089 · Manufacture of other food products n.e.c.
Founded
24. august 2023
Share capital
DKK 94.971
Employees
9 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2025-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af bestyrelsesformanden og et bestyrelsesmedlem i forening, eller af den samlede bestyrelse.
Company purpose
Selskabets formål er at drive virksomhed inden for bioøkonomi ved at udvikle innovative fødevarer og ingredienser og fremme og eskalere fermenteringsteknologier, herunder investere i virksomheder inden for dette felt, samt aktiviteter, der efter bestyrelsens skøn er forbundet dermed.
Address
Kirstinehøj 1
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2024 | 2025 |
|---|---|---|
| Revenue | -393 | -225 |
| Staff expenses | -3.188 | -5.011 |
| EBITDA | -3.582 | -5.236 |
| Depreciation & amort. | -9 | -173 |
| EBIT | -3.591 | -5.409 |
| Net financials | 1 | -205 |
| Profit before tax | -3.590 | -5.614 |
| Tax | -0 | -0 |
| Net profit | -3.590 | -5.614 |
| Item | 2024 | 2025 |
|---|---|---|
| Total assets | 1.525 | 20.102 |
| Equity | 450 | 16.371 |
| Long-term debt | 0 | 3.055 |
| Short-term debt | 1.075 | 676 |
| Total debt | 1.075 | 3.731 |
EBITDA margin
-523604800.0%
This company
15.8%
Market median
-3313954530% vs market
20242025
Equity ratio
81.4%
This company
38.2%
Market median
+113% vs market
20242025
Return on equity
-34.3%
This company
18.4%
Market median
-286% vs market
20242025
Net profit margin
-561376000.0%
This company
8.1%
Market median
-6930568001% vs market
20242025
Asset turnover
-0.01×
This company
1.12×
Market median
-101% vs market
20242025
Debt / equity
0.23×
This company
0.62×
Market median
+63% vs market
20242025
- Annual report 2025Filed via CVR / Virk · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via CVR / Virk · Period 2023-08-24 – 2024-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
TP Management | Management | 2023 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2025 | — | — | |
| Chairman | 2025 | — | — | |
| Board of Directors | 2026 | — | — | |
| Board of Directors | 2023 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
KAAL Industries ApS | Company | 25.0% | 25.0% | 2025 |
Ferm Swan Holding ApS | Company | 25.0% | 25.0% | 2025 |
| Individual | 15.0% | 15.0% | 2025 | |
WHITE LABS - COPENHAGEN ApS | Company | 10.0% | 10.0% | 2025 |
Hakoah New Ventures ApS | Company | 5.0% | 5.0% | 2025 |
Future5 ApS | Company | 10.0% | 10.0% | 2023 |
8299 A/S | Company | 10.0% | 10.0% | 2023 |
JACOB LEE ØRNSTRAND HOLDING A/S | Company | 10.0% | 10.0% | 2023 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Ferm Holding ApS
Swan Neck Bio ApS Board members of Swan Neck Bio ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Troels Prahl Jørgensen | Management | 0 companies |
| Jacob Nelson Lee Ørnstrand | Board of Directors | 0 companies |
| Kasper Hulthin Rasmussen | Chairman | 0 companies |
| Nicolai Buhl Andersen | Board of Directors | 0 companies |
| Mark Emil Tholstrup Hermansen | Board of Directors | 0 companies |